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The Challenges of Type 1 Diabetes and New Psychoactive Substance Misuse 
 
Jacqui Charlton, Alessio Albanese, Liz Brodie 
 
Abstract: 
Aim: Substance misuse, specifically novel psychoactive substances (NPSs), can have multiple 
effects on physical and psychological health and well-being. This is of particular concern to 
people with Type 1 Diabetes (T1DM) as their use may impact on effective glucose 
management and may result in acute complications and deleterious consequences. This review 
aims to investigate the physical and psychological effects of NPSs and traditional illicit drug 
use on glycaemic control and corresponding self-care for people with T1DM.  
 
Method: We performed a literature search of seven electronic databases for articles published 
between 2011-2017, using MeSH search headings: diabetes, young people, substance misuse, 
novel psychoactive substances, club drugs, street drugs, rave drugs, legal highs, designer drugs, 
research chemicals, glycaemic control, ketoacidosis, self-management, and harm reduction. 
 
Results: Literature was scant, despite the available evidence of increased substance use in the 
UK. There is a paucity of evidence about the effects of NPSs and traditional illicit drug use on 
glycaemic control, and a lack of educational information which could be used to inform users 
with T1DM and HCPs about their risks and preventative self-care strategies.  
 
Conclusion: Patient awareness of potential problems with regard to safety is an essential 
component of effective risk management, health protection and glycaemic control. HCPs also 
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require evidence based information regarding these components in order to communicate and 
empower patients who choose to participate in this potential risky behaviour.  
 
Key words: Diabetes, young people, substance misuse, glycaemic control, ketoacidosis, self-
management, harm reduction. 
 
Key points:  
1. NPSs have caused a change in pattern of recreational drug use. An increasingly 
common trend is poly-drug use which includes alcohol consumption.  
2. It is unlikely that illicit drug users with T1DM would volunteer information if they are 
not introduced into the dialogue by the HCP.  
3. Diabetes care teams should be mindful that illicit drug use may be common in 
adolescents with T1DM, with the most popular being cannabis (and NPS equivalent), 
ecstacy, cocaine, speed and mephedrone (NPS).   
4. The main risks of illicit drug use appear to be hyperglycaemia, and DKA can be 
precipitated by ketosis caused by stimulant-enhanced lipolysis from sympathetic over-
activity. 
5. Illicit drugs along with the cognitive impact of substance intoxication on decision 
making for self-care, plus predisposing poor glycaemic control, can result in DKA. 
6. Similarities between the symptoms of hypo and hyperglycaemia and the effects of NPSs 
and illicit drugs could obscure the identification of a glucose problem, and the only 
method of identifying the cause of the effect/symptom is by blood glucose testing. 
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Introduction 
New psychoactive substances (NPSs) which first emerged around 40 years ago, are also 
described as club drugs, designer drugs or research chemicals. These were misleadingly 
known as ‘legal highs’ due to their initial exclusion from existing drugs legislation 1 within 
the UK. This enabled easy availability from high street shops and multiple online sources 2, 
which appealed to young people as the dark net was less favourable to younger NPS users 3.  
 
NPSs are synthetic compounds sought for their intoxicant effects and perceived lower risk 
and cost than their traditional illicit drug equivalents, and have caused a change in patterns of 
recreational drug use away from more traditional substances. Their colloquial names such as 
bath salts, spice, and plant foods also enhance the idea of reduced risk. However recently, 
legislation in the UK 4 has categorised NPSs alongside their illicit counterparts such as 
cannabinoids, opioids and stimulants.  
 
There is evidence to suggest that school students are increasingly attracted to NPSs through 
information gained from peers, social media and other online sources 5. However, only five per 
cent of 15-year olds report using one or more NPSs, which is lower compared to 17% using 
cannabis, and comparable to five percent of ecstasy or four percent of cocaine users 6. 
Interestingly, the five percent of NPSs users report consuming synthetic cannabis (72%), and 
mephedrone (71%), which mimic ecstasy and cocaine. In England and Wales, 20% of 16-24 
year olds and 15% of 11-15 year olds have used an illicit drug in the last year. From these, 9% 
and 5% have used cannabis respectively 7. Measham and colleagues 8 suggests that NPSs are 
now frequently used to supplement rather than replace more traditional illicit drugs, thus 
exacerbating the acute effects and the risks to health for users 5. In 2015 drug misuse in England 
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and wales accounted for nearly 1 in 8 deaths among people in their 20s and 30s, however 
highest rates of drug misuse deaths are currently are among people in their 30s and 40s. 
 
There is also an increasing trend of poly-drug use which refers to the use of more than one drug 
taken at the same time or sequentially by an individual 9. This pattern also includes alcohol 
consumption 10,11.  
Due to the large, and increasing number of NPSs that are available 12,13, and with resulting 
changes in recreational drug-use patterns including regional variations, difficulty arises for 
HCPs to conduct assessments and plan care. These present challenges to HCPs and users alike, 
with the additional complication resulting from the fact that T1DM can exacerbate further. 
 
Vulnerability of young people with T1DM and NPS use 
In the UK, there are approximately 400,000 people with T1DM 14. For a young person with 
T1DM, maintaining acceptable glucose control whilst participating in lifestyle activities with 
peers can prove challenging. Difficulties may arise when experiencing new situations such as 
initiation to alcohol consumption, sexual activity, leaving home, diminishing parental 
supervision, starting higher education courses and employment, and meeting new friends 15. 
Realistically, diabetes management may not necessarily be a priority during this period in their 
lives. These activities and related social environments such as bars/clubs, music festivals and 
student social spaces can increase the exposure to illicit drug use. It is also suggested that young 
people with chronic conditions may be at greater risk of engaging in high risk behaviours 
compared to their healthy peers 16. In addition, other factors such as homelessness, early life 
trauma, pre-existing mental health problems and sexuality, can influence both the initiation 
into drug use and high-risk behaviors 17.  
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The prevalence of illicit drug use. 
Prevalence of use within our clinic populations is important to understand in order to gauge the 
extent of risk amongst young people.  In 2012, Lee and colleagues 18 showed that recreational 
drug use was most commonly reported among respondents under the age of 20, and least 
commonly among respondents aged 25 to 29 years. Ng et al. 19 indicated that 29% of 85 study 
participants aged between 16 and 30 years reported using street drugs. Of those, 68% habitually 
took street drugs more than once a month, 72% of whom were unaware of the adverse effects 
of drug taking on the management of T1DM. Snyder et al. 10 questioned 60 adolescents with 
T1DM aged between 12 and 20 years about their use of alcohol and tobacco alongside illicit 
substances. This study reported that the prevalence of substance use was 36.7% among 
participants. Of these, older participants and those with depression were more likely to engage 
in illicit substance use.  
 
With regard to glycaemic control, Snyder et al. 10 suggested that illicit drug use was not 
correlated to glycaemic control or diabetes self-management. Whereas Lee et al.18, showed that 
poor glycaemic control was up to three times more common among drug users compared with 
non-users. In this group, drug use was associated with poor glycaemic control, independent of 
age, gender, duration of diabetes and tobacco smoking. Ng et al. 19 confirmed that DKA and 
poor glycaemic control in young adults with T1DM may be caused by ‘street drug’ use. These 
results were echoed by Wong and Holt 20 who also concluded that HCPs should recognise that 
street-drug use, including NPSs, may be associated with poor glycaemic control and increased 
risk of DKA. While acknowledging that the results are derived from older studies, these data 
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suggest that diabetes care teams should be mindful that illicit drug use are common in 
adolescents with T1DM.  
 
 
Diabetes HCP and patient interaction 
It is apparent that the use of illicit drugs by young adults is not deterred by having the diagnosis 
of T1DM 10,19 which can present several challenges for both the young person and the diabetes 
HCP. Lee et al 18 indicated that from a survey of 388 T1DM respondents, only 7% informed 
HCPs about their illicit drug use and that it was unlikely for users to volunteer information 
about substance use unless they were introduced into the dialogue by the HCP.  
Hence, one crucial element in a consultation is how to approach the subject. However, it is 
understood that the unlawful use of substances along with confidentiality issues may hinder 
the initial opening of conversation. From an HCP perspective, considerations around patient 
interaction, communication and engagement are important, as is open dialogue. However, once 
discussions start, the HCP has potentially limited awareness of the use, knowledge, risks, and 
evidence to provide education and support 20,11. This can result in a lack of confidence in how 
to respond to a disclosure of illicit drug use which may lead to avoidance of further discussion 
around NPSs or other substances. As Lee et al. 11 suggested, the lack of understanding of the 
effects of substance properties makes patient advice and education difficult. For NPSs, the 
unknown composition of the psychoactive agent adds to the challenges not only to users who 
rely on sellers’ descriptions 21 but also to HCPs, which limits their ability to provide topical 
advice on risks and harms associated with NPS use. For clinical practice, existing knowledge 
around the effects of traditional illicit drugs with similar NPS groupings should be used for the 
possible impact on glycaemic control (see table 1). The lack of patient information both in 
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leaflet form and digital resources may result in the subject being overlooked during 
consultations.  
 
The effects on glucose control 
Existing literature reports high mortality from acute diabetes-related events associated with 
substance misuse 22. In relation to blood glucose management, the main risks of illicit drug use 
(excluding NPSs as no literature was found) appear to be hyperglycaemia and life-threatening 
diabetic ketoacidosis (DKA). The most commonly used substances are cannabis (and NPS 
equivalent), ecstacy, cocaine, speed and mephedrone (NPS). In 2008, Lee et al 23 reported on 
19 patients with T1DM who presented with DKA during a 10-month period. Of these, 10 
patients reported illicit drug use in the 48 hour period before presentation, including cannabis 
(n=8), ecstasy (n=6), ketamine (n=6), benzodiazepines (n=3) and heroin (n=3), with seven 
patients being poly-drug users. Within this study there was no reference to NPS usage, which 
may be because in 2008 the awareness and availability of NPSs was not to the extent that it is 
now. However, with regard to illicit drug use, resources are limited for people with T1DM to 
highlight associated risks in relation to blood glucose levels, and important preventative self-
care strategies. This is somewhat understandable as original research is rare, possibly due to 
researcher unawareness of the problem, or difficulties obtaining ethical approval due to 
legalities of investigating illicit substances and potential glycaemic consequences. In 
comparison to illicit drug use, alcohol, which is a licit substance, is known predominantly for 
hypoglycaemic risks and to a lesser extent potential hyperglycaemia. It is known that there are 
some safe-drinking guidelines available which focus around safe consumption and include self-
care strategies including carbohydrate consumption, possible insulin adjusting, and the benefits 
of blood glucose testing. Poly-drug use guidelines combining alcohol and illicit drug use are 
now required. 
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The current upsurge in availability of NPSs over the last decade has led to an emerging body 
of literature about NPSs and their effects on young people. However, there is an absence of 
evidence demonstrating the clinical effects of NPS use and impact on people with T1DM. The 
list of effects and resultant clinical risk is challenging to summarise due to the variety of 
available substances and their frequently changing chemical composition. Nonetheless, Table 
2 attempts to provide an overview of the effects and clinical impact of the most commonly 
encountered NPSs along with their illicit drug counterparts.  
 
Specific drug types and effects 
As described previously, of most concern to young people regarding NPSs, are synthetic 
cannabinoids and mephedrone, which primarily has a stimulating effect and has been widely 
used since 2009 24, with highest use occurring in those under 21 years of age. Despite common 
and frequently used drugs within the cannabinoid group, no evidence is reported regarding 
T1DM. However, given that a common effect of cannabis is increased appetite, one can 
speculate that this can lead to hyperglycaemia unless self-care regarding insulin administration 
is carried out. 
 
With regard to mephedrone, the perceived positive effects such as euphoria, overall 
disinhibition, along with the sense of energy experienced with this stimulant drug 25, 26 can also 
have a negative impact on health, and could greatly influence attention to diabetes self-care. 
Wong and Holt 20 reported a case study which focused on an 18-year-old male with T1DM, 
who was admitted with DKA following mephedrone use. The patient was a regular user, and 
on admission was unable to remember insulin administration or food consumption. In this 
instance, mephedrone impaired individual awareness and ability to self-manage their diabetes.  
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In addition, there is some evidence to support the physiological effect of other illicit drugs with 
stimulant properties such as MDMA (ecstasy), amphetamine (speed), and cocaine which can 
cause dehydration and DKA 20. It is already recognised that MDMA requires increased insulin 
doses 18, and interestingly despite the lack of knowledge related to self-management, 
respondents reported an increase in insulin dose intake by 100-150 percent in an attempt to 
reduce hyperglycaemia. Lee and colleagues 23 also explained that hyperglycaemic properties 
of cannabis, heroin and ecstacy can precipitate DKA by ketosis-caused, stimulant-enhanced 
lipolysis from sympathetic over-activity. Ketamine can also cause severe acidosis. These drugs 
along with a predisposition to poor glycaemic control and inadequate insulin administration 20, 
can result in DKA. Lee et al. 23 indicate that people at risk have poor glycaemic control due to 
insulin underutilization, which also was shown by Lee et al. 18 and Ng et al 19.    
 
Challenges and impact on glycaemic control. 
Similarities between the symptoms of hypo and hyperglycaemia and the effects of NPSs and 
illicit drugs, complicate the clinical picture for both patients and HCPs, which is shown in 
tables 1 and 2. This could obscure the identification of a glucose problem and unfortunately 
the only method of identifying the cause of the effect/symptom is by blood glucose testing, 
which is often ignored by this patient group 18. The cognitive impact of substance intoxication 
on decision making for self-care is also under-recognized, especially with the influence on 
insulin compliance. It is also known that poor glycaemic control can be associated with chaotic 
lifestyles, denial of chronic disease management, and poor social support 27. These factors can 
increase the risk of depression in people with diabetes which in turn, can exacerbate drug use 
10.  
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Reassuringly, Ng et al. 19 reported that 28% of their study cohort were aware of the adverse 
effects on diabetes management when partaking in illicit drug use, and interestingly 48% 
inform friends about having diabetes and perform blood glucose monitoring. From a patient 
perspective a clinical emergency tends to be perceived as hypoglycaemia rather than 
hyperglycaemia, thus the risks of ketoacidosis may be overlooked. The stimulant drugs causing 
frenetic behaviour and increased activity such as cocaine, MDMA and mephedrone could cause 
fear of hypoglycaemia due to the glucose lowering effects of increased activity. Also, some 
situations may cause the user to be concerned about recognising or treating dangerously low 
glucose levels. Examples of which are epitomised by opioids, cannabinoids, empathogens and 
dissociatives. This may encourage preventative hypoglycaemic self-care strategies which 
would be insulin reduction or omission, or increased CHO consumption. For a user with 
T1DM, in order to understand self-care strategies the basic physiological effects of insulin and 
glucagon must be understood. Increased activity requiring increased blood glucose for cellular 
energy will result in glycogenosis. If exogenous insulin is not administered, hyperglycaemia 
and DKA can occur. This is a difficult concept and situation for the patient and HCP to discuss 
and understand without individual glucose monitoring to reveal the effect of the drug and 
inform appropriate and safe insulin administration.  
 
In view of this, it should be noted that the wide-ranging health implications of all substances 
are not simply due to the pharmacology of the drug, but they are greatly influenced by lifestyle, 
which can have an impact on diabetes. Particular concerns are related to dietary neglect, lack 
of self-care and lack of medication adherence.  
 
Alcohol and poly-drug use  
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Alcohol is now frequently used as part of a poly-drug culture and is particularly used in binges 
associated with NPSs, and most commonly associated with mephedrone, which increases 
disinhibition and high-risk behaviour 25. Alcohol is a depressant, and its effects and risks on 
glucose control in T1DM are recognized, but self-care advice is limited 28. The effect of alcohol 
on glycaemia depends on the type of beverage and amount consumed 29. In relation to poly-
drug practice, beverages such as cider and alcopops will cause hyperglycaemia, whereas beer, 
wine and spirits can cause hypoglycaemia and glucose variability.  
Regarding these patterns associated with substance use, a lack of understanding is common 30. 
This adds to the severe acute complication risk when combined with illicit substances. Ecstasy 
used alongside alcohol, can impair thermal regulation and increase dehydration, and lead to 
sympathetic hyperactivity that may result in impaired cardiac functioning 31,32.  
 
Cognitive effects in relation to self-care and blood glucose management 
Current findings suggest a shortage of self-care strategies to ensure safety and risk reduction 
for potential severe complications, especially DKA 11. It is therefore not surprising that users 
are oblivious to the danger of effects from both the substance and diabetes management, 
especially regarding insulin administration 19. The effects of drugs and their impact on hypo 
and hyperglycaemic symptoms without blood glucose testing could be misunderstood and 
cause inappropriate insulin administration as described by Lee et al. 18, where it was 
demonstrated that MDMA users self-administer up to more than double the usual insulin dose. 
However, there are limited resources available for people with T1DM regarding illicit drug 
use, associated risks in relation to blood glucose levels, and related preventative self-care 
strategies. Due to the multiple variables associated with young people and substance use, 
recommendations are difficult to collate 11. Until specific evidence based guidelines are 
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available, HCPs should be aware of existing harm reduction advice which is advocated for all 
users of NPSs and illicit drugs (see table 3).   
 
Conclusion 
In summary, this review confirms that for a person with T1DM using illicit drugs presents a 
risk of hyperglycaemia and DKA. The drug effects may also obscure the recognition of 
hyperglycaemia or hypoglycaemia, and compromise self-care awareness and behaviour. In 
view of this we should be targeting the at-risk population with a specific detection and 
prevention strategy, which could be included in HCP review appointments leading onto the 
discussion of self-care strategies. This review has highlighted the dearth of evidence 
regarding an effective intervention, and the need for the development of educational 
resources for users with T1DM and HCPs to prevent potentially lethal consequences. For 
HCPs to effectively support and educate people with T1DM who use substances, they must 
know the effects of different drug groups on glycaemic control and self-care strategies which 
can prevent complications and fatalities of this under-reported health risk. Regional 
variations in drug-taking behaviours would indicate a flexible/bespoke approach may be 
required. With the recent legislation on Flash glucose monitoring on NHS prescriptions 
becoming available this may help HCPs and illicit drug-users understand the impact on 
glucose control. 
 
Acknowledgement: Thanks to Mark Adley for his kind permission to use the Drugs Wheel.  
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Table 1: The Drugs Wheel: a new model for substance awareness. Developed in 
collaboration with DrugWatch and reproduced in its entirety from: www.thedrugswheel.com 
(copyright CC-BY-NC-SA 4.0). 
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Table 2: Illicit drug and equivalent NPS, effects and potential glycaemic risks  
N.B: NPSs highlighted in red, possible causes of hyper/hypoglycaemia highlighted in blue. 
 
  
Drug group Example  Effects  Effects similar to 
hypo/hyperglycaemia and/or 
risks for hypo/hyperglycaemia 
Stimulants  Cocaine, Ecstacy 
(MDMA), 
Amphetamine, 
Mephedrone.   
Euphoria, relief from 
fatigue, increased 
activity levels, sense of 
well-being, confidence. 
Mood swings, visual and auditory 
hallucinations, sweating, nausea, 
dehydration, lowered appetite. 
Opioids Heroin, 
Methadone, 
Dihydrocodeine 
Fentanyl  
Kratom 
Euphoria, feelings of 
safety and warmth, sense 
of well-being, 
confidence. 
Sweating, drowsy. 
Hallucinogens 
and 
psychedelic 
drugs 
LSD, Psilocybin Euphoria, heightened 
sensory awareness, 
connectedness, 
hallucinations  
Psychosis, anxiety  
Dissociative 
drugs 
 
 
Ketamine, Salvia,  
Nitrous Oxide 
Out of body, calm 
relaxed, numb, unable to 
move, can distort 
perceptions of sight and 
sound and create 
feelings of detachment 
or dissociation from the 
self and the 
environment. 
Ketamine can precipitate DKA in 
T1DM. The metabolic acidosis 
can be severe. 
  
Empathogens  MDMA Warm, mellow, sense of 
belonging, depression 
 
Sweating, mood swings. 
Cannabinoids  Cannabis, 
Synthetic cannabis  
Calm, relaxed, excited, 
giggling, energetic. 
Dry mouth, increased appetite, 
loss of memory. 
Depressants  Diazepam, 
Etizolam, 
Temazepan, 
Gabapentin, Kava, 
Solvents. 
  
 
Relaxed, disinhibition.  
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Table 3: Current advice regarding general harm reduction and diabetes management 
 
 
 
  
Current advise for people with T1DM (Hicks 2017) 
Advice should be given to maintain safety prior, during and after taking drugs or alcohol, 
including the following:  
 Carry identification stating that the user has diabetes and requires medication. 
 Check blood glucose levels before using, and after “coming down”.   
 If low, have some food, and drink sugary drinks in between water, especially if there 
is no appetite.  
 Drink plenty of water.  
 Eat a meal containing carbohydrate as soon as possible after coming down.   
Harm reduction (adapted from Crew2000 2016) 
 Know your substance and try to buy from familiar sources, and avoid injection. 
 Avoid using alone, and tell people what you have taken. 
 Avoid mixing different drugs and alcohol, and wait at least an hour before re-
dosing.  
 Take regular breaks when dancing, and keep hydrated.  
 Seek immediate help if you start to feel unwell.  
16 
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